Cantor Fitzgerald maintains Neutral rating on Centene stock amid state-specific Medicaid shifts

Cantor Fitzgerald reiterated a Neutral rating and $38 price target for Centene (CNC), citing potential upside from its current trading level but emphasizing that state-specific Medicaid enrollment shifts will significantly impact 2026 performance, creating varied outcomes across healthcare payors. This nuanced outlook emerges despite Centene reaffirming its 2025 adjusted EPS guidance of $1.75, which exceeds the $1.64 consensus, and other analysts maintaining positive ratings based on strong ACA and Medicaid trends. Investors should closely monitor granular state-level Medicaid data, as differing state policies and 2026 marketplace rates will be critical drivers for Centene's future trajectory.

Analysis

Centene (CNC) presents a moderately positive but nuanced outlook, underpinned by its reaffirmed 2025 adjusted EPS guidance of approximately $1.75, which significantly exceeds the consensus estimate of $1.64. This strong guidance has been met with favorable analyst actions, including a price target increase to $39 from Truist Securities (Buy rating) and an Outperform reiteration from Bernstein ($36 target), both citing stable Medicaid trends and positive Marketplace developments. However, this optimism is tempered by a more cautious stance from Cantor Fitzgerald, which maintained a Neutral rating and $38 price target. Cantor's analysis highlights a critical future variable: the significant impact of state-specific Medicaid enrollment shifts on 2026 performance. The firm notes that Centene and Elevance Health are experiencing the largest such shifts, and forecasting will become challenging due to inconsistent state-level approaches to budget cuts and work requirements. This divergence creates a key analytical tension, pitting Centene's strong near-term execution and positive current trends against significant, state-driven policy uncertainty that could materially affect its longer-term earnings trajectory.

Key Decisions for Investors

• Investors should weigh Centene's strong near-term fundamentals, highlighted by its above-consensus 2025 EPS guidance, against the significant forward-looking risk posed by state-level Medicaid policy and enrollment shifts.
• It is critical to monitor granular, state-by-state Medicaid data for both Centene and its peers, as this will be the primary leading indicator for performance and forecast accuracy heading into 2026.
• Given the divergence in analyst ratings and price targets, ranging from $33 to $39, investors should consider the stock's potential upside from its current valuation while remaining cautious about the heightened policy uncertainty that could introduce volatility.